Skip to content

Effects of Early Rehabilitation on Outcomes and Inflammation in Acute Ischemic Stroke Patients with Asymptomatic Intracerebral Hemorrhage after Thrombectomy

Effects of Early Rehabilitation on Outcomes and Inflammation in Acute Ischemic Stroke Patients with Asymptomatic Intracerebral Hemorrhage after Thrombectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100229
Enrollment
Unknown
Registered
2025-04-07
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Control Group:Standard Conventional Rehabilitation

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients who met the indications for intravenous thrombolysis or mechanical thrombectomy in acute ischemic stroke, had no contraindications, and underwent mechanical thrombectomy; 2.Patients showing non-symptomatic intracranial hemorrhage (Heidelberg Bleeding Classification Grade 1) on head CT within 24 hours post-procedure; 3.Patients with stable vital signs (resting heart rate 50-100 bpm; systolic blood pressure 100-160 mmHg; SpO2 >=90%) and a Glasgow Coma Scale (GCS) score >=9.

Exclusion criteria

Exclusion criteria: 1.re-stroke modified Rankin Scale (mRS) score >=2; 2.Severe dysfunction of major organs (heart, liver, kidneys, etc.) or concurrent serious neurological disorders (e.g., brain tumors); 3.Patients unable to cooperate with rehabilitation training and assessment (e.g., those with severe cognitive impairment or mental disorders); 4.Patients or their legal representatives declining participation.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;

Secondary

MeasureTime frame
Modified Barthel Index;National Institutes of Health Stroke Scale;Fugl-Meyer Assessment ;Interleukin-6;Interleukin-10;Neutrophil-to-Lymphocyte Ratio;Matrix Metalloproteinase-9;Soluble Suppression of Tumorigenicity 2;

Countries

China

Contacts

Public ContactMu Shanshan; Wan Chunxiao

Tangshan People's Hospital; Tianjin Medical University General Hospital

850069606@qq.com+86 151 3392 1316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026